Kornimate/medical-research-clean huggingface dataset:
mother-infant connection strategy program

Conditions: Psychological; Mother-Infant Interaction

Summary: this study evaluated the long-term effects of an online mindfulness-based program on the psychological distress and mother-infant bonding of women

the aim of this study was to test the efficacy of an online mindfulness program in reducing women's perceived stress, anxiety, depression, and in enhancing mindfulness and mother-infant bonding compared to a control group. the investigators hypothesize that the use of an online mindfulness program or an eight-week mindfulness program by the two experimental groups will lead to improved mood symptoms and mother-infant bonding compared with the control group. a randomized controlled trial comparing three groups of healthy, singleton pregnant women was conducted using the random allocation software (saghaei, 2004). we used g-power 3.1.9 for windows to analyze the minimum effect size that would be statistically significant with an 80% probability, using an alpha error probability of 0.05 in the "anova: repeated measures, between factors" option. we inputted 3 for the number of groups, 4 for the number of measurements, 0.5 for the correlation between repeated measures, and factored in a 20% attrition rate. there are 41 women in each group.

Eligibility criteria:
inclusion criteria: * subjects were at the age over 18 * could speak and read chinese fluently * willing and be ale to attend the education program exclusion criteria: * taking medication for diagnosing mental illness * with complicated or high-risk pregnancies

Keywords: mindfulness, anxiety, depression, mother-infant interaction
clinical trial of several contact lenses in extended wear

Conditions: Myopia

Summary: the study is to clinically evaluate currently marketed contact lenses when used in an extended wear modality of up to seven days/six nights.


Eligibility criteria:
inclusion criteria: * be of legal age, and be between 18 and 39 years of age. * signed written informed consent and investigator to record this on case report form (crf) in appropriate space. * require a visual correction in both eyes (monovision not allowed) * require a soft contact lens spherical correction between -0.50 and -9.00d. * have an astigmatic correction less than 1.50d in both eyes. * be able to wear the lens powers available for this study. * be able to regularly wear the lenses on a 7 day/6 night extended wear basis (e.g. does not regularly swim more than once a week) * be correctable to a visual acuity of 20/30 or better in each eye. * have normal eyes with no evidence of abnormality or disease. for the purposes of this study a normal eye is defined as one having: * no amblyopia. * no evidence of lid abnormality or infection. * no clinically significant slit lamp findings * no other active ocular disease. * no previous ocular surgery. exclusion criteria: * requires concurrent ocular medication. * any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * no clinically significant (grade 3 or 4) slit lamp findings including corneal edema, corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection, or any other abnormality of the cornea that would contraindicate contact lens wear. * diabetic. * infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., hiv). * pmma or rgp lens wear in the previous 8 weeks. * has had refractive surgery. has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study. * abnormal lacrimal secretions. * pre-existing ocular irritation that would preclude contact lens fitting. * keratoconus or other corneal irregularity. * pregnancy, lactating or planning a pregnancy at the time of enrollment only. * participation in any concurrent clinical trial. * currently wearing b\&l purevision, ciba o2 optix, ciba night \& day, coopervision biofinity, vistakon acuvue® oasys, or vistakon acuvue®2 on an ew basis * has had previous adverse event(s) contraindicating ew e.g. mk or greater than 2 corneal scars which appear to be contact lens related (e.g. not trauma related). * has had an eye injury or surgery within the last eight weeks.
buprenorphine and naloxone combination study - 10

Conditions: Heroin Dependence; Opioid-Related Disorders

Summary: the purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

the objective of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

Eligibility criteria:
inclusion criteria: male/female between the ages of 21 and 45. within 15% of ideal body weight. no oral pathology that would interfere with the sublingual absorption of the medication. experienced in the use of opiates but not dependent. exclusion criteria: lft's exceeding than 3x's normal. history of seizure. opiate dependent.
neurohumoral mechanism of deferent frequency transcutaneous electrical acupoint stimulation(teas)

Conditions: Hypotension

Summary: the purpose of this study is to explore the neurohumoral mechanism of deferent frequency teas pretreatment.

patients were randomly assigned to three groups, receiving teas 30min before anesthesia. the frequency of high frequency group is set to 10/50hz, low frequency group is 2/10hz, and the fake stimulation group only attach electrodes without electric current. acupoint selection is bilateral neiguan points(pc6). venous blood is collected 4ml before and immediately after teas respectively. heart rate variability is monitored continuously during the 30min teas. the adverse events recorded.

Eligibility criteria:
inclusion criteria: * age 18yrs-65yrs * asa 1-2 * scheduled for elective operation under general anesthesia * bmi 18-30kg/m2 * informed consented exclusion criteria: * contraindications to teas * communication difficulty with researchers * addicted to alcohol, analgesics or other drugs * cardiac insufficiency or high blood pressure without controlled * hepatic or renal dysfunction * participate in the other clinical trial 3 month before the enrollment
aging with hiv and neurocognitive decline, a follow-up study

Conditions: HIV Infections

Summary: the anrs ( agence nationale de recherches sur le sida et les hépatites virales) 0093s aging hand study is to assess whether plhiv (people living with hiv) initially between 55-70 years of age at baseline analysis under antiretroviral therapy have accelerated decline of neurocognitive function after 6 years of follow-up. aging hand is a french, multicentric, longitudinal, transversal, prospective study with inclusion of 290 plhiv.

the primary objective of this study is to analyze whether plhiv initially aged between 55-70 years of age at baseline under antiretroviral therapy have accelerated decline of neurocognitive function after 6 years of follow-up in comparison with an age, gender and educational level matched hiv non-exposed control group from the constances cohort. the secondary objectives of this study are : * to determine the prevalence of neurocognitive impairment (nci) according to the frascati criteria, clinical consensus and alternative classifications, after additional accrual of individuals aged 55 to 76 years for a more precise and extensive age range analysis of nci * to describe the incidence and prevalence of the frailty syndromes, and their relation with co-morbidities and nci, using the fried score as a measure of frailty * to constitute a plasma and serum biobank for biomarkers study related to the aging of plhiv

Eligibility criteria:
inclusion criteria inclusion criteria for plhiv for the longitudinal study: * having participated in the anrs ep58 hand 55-70 study * a signed informed consent * to be affiliated and benefit from the french social security inclusion criteria for plhiv for the transversal study (only for new subjects): * hiv-1 * aged between 55 years and 76 years; * with a viral load \< 50 copies/ml for more than 24 months (with a minimum of 3 available viral loads 6 months prior to inclusion). blips -defined by a transient increase in viral load- are allowed if \< 200 copies/ml, with a maximum of two blips within 24 months; * with a cd4 (cluster of differentiation 4) count at inclusion ≥ 200 cells/µl for more than the last 12 months (with a last available cd4 count \< 6 months of inclusion); * a signed informed consent * to be affiliated and benefit from the french social security exclusion criteria non-inclusion criteria for plhiv for both the longitudinal and transversal studies: * an isolated hiv-2 infection * confused or with an ongoing neurological disease * presenting psychiatric syndromes interfering with cognitive evaluation; * with sensorial loss, analphabetism or language barriers rendering the interpretation of tests difficult. * with recent extensive neurocognitive evaluation within 6 months prior to inclusion * with neurological disease with ongoing clinically relevant sequela * participating in another research program, prohibiting the participating in additional research * vulnerable: minors, under guardianship or curatorship, or persons deprived of liberty for administrative or judiciary reasons

Keywords: hiv aging neurocognitive decline frailty syndromes
babies living safe and smokefree

Conditions: Second Hand Tobacco Smoke; Nicotine Dependence

Summary: the purpose of this randomized controlled trial is to develop and test the efficacy of a multilevel, multimodal intervention designed to modify maternal smoking behavior to reduce children's exposure to secondhand tobacco smoke (primary outcome) and promote their smoking cessation (secondary outcome). low-income mothers who smoke will be enrolled. mothers will be recruited from the supplemental nutrition program, women, infants and children (wic) clinics. all mothers visiting wic clinics will receive a clinic-level intervention, which consists of nutrition counselors following an "ask, advise, and refer" protocol to identify if their children are exposed to secondhand tobacco smoke, advise mothers who smoke about the harms of such exposure and the benefits of reducing exposure, and referring mothers to the trial. screened eligible mothers will be consented and randomized to an attention control condition focused on nutrition (ctl) or to an experimental (exp) multimodal behavioral intervention that integrates telebased counseling to promote the reduction of child secondhand smoke exposure (shse) and maternal smoking with an adjunct smoking cessation mobile app and nicotine replacement therapy use. the investigators will test the primary hypothesis that relative to children in the ctl condition, those in the exp condition will have lower exposure shse as measured by mothers' reports and child cotinine levels. the investigators will also test the secondary hypothesis that relative to mothers in the ctl condition, those in the exp condition will have higher bioverified 7-day point prevalence quit rates. in addition, the study will: (a) evaluate if specific psychosocial and behavioral factors-- social support, urge coping skills, self-efficacy, and shse protective behaviors--mediate the effects of the exp intervention on outcomes and (b) explore whether other residential smokers, level of nicotine dependence, depressive/anxious symptoms, weight concerns, intervention dosage, and pregnancy status predict outcomes and moderate treatment effects.


Eligibility criteria:
inclusion criteria: * english speaking * female * at least 18 years of age * parent or legal guardian of child under 6 yrs old who lives with them at least 4 days/wk * smokes exclusion criteria: * non-nicotine drug dependence * active psychiatric disturbance (bipolar, schizophrenia, psychosis) * inadequate health literacy * pregnant * no smartphone
distal versus conventional transradial artery access for coronary catheterization in patients with stemi

Conditions: ST Elevation Myocardial Infarction; Coronary Artery Disease; Distal Transradial Artery; Transradial Artery; Coronary Catheterization; Percutaneous Coronary Intervention; Primary PCI

Summary: recently, a novel distal transradial, through anatomical snuffbox, approach has been proposed for undertaking percutaneous coronary angiography and interventions. the existing literature has evaluated distal transradial access (dtra) as a feasible and safe approach, with faster hemostasis, lower rates of periprocedural complications and reduced incidence of radial artery occlusion (rao). aim of the present study is to compare dtra versus conventional tra access in patients with stemi undergoing coronary angiography and interventions regarding peri- and post-procedural characteristics.

gaining vascular access is the first, mandatory step for undertaking percutaneous coronary angiography and interventions. the recent guidelines, published by european society of cardiology (esc), american college of cardiology (acc), american heart association (aha) and society for cardiovascular angiography and interventions (scai), propose tra as the gold standard for acute coronary syndromes (acs), chronic coronary syndrome (ccs) percutaneous coronary interventions (pci). recently, a novel distal transradial, through anatomical snuffbox, approach has been proposed. the existing literature has evaluated distal transradial access (dtra) as a feasible and safe approach, with faster hemostasis, lower rates of periprocedural complications and reduced incidence of radial artery occlusion (rao). mutual point of all the previous rcts is that excluded patients suffering from st-elevation myocardial infraction (stemi). aim of the present study is to compare dtra versus conventional tra access in patients with stemi undergoing coronary angiography and interventions regarding peri- and post-procedural characteristics.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * indication: st-elevation myocardial infraction exclusion criteria: * non-palpable radial artery * previous cabg * anatomical restrictions for forearm approach * hemodynamic instability * previous radial artery catheterization from the same arm during the last 30-days

Keywords: st elevation myocardial infarction coronary artery disease distal transradial artery transradial artery coronary catheterization percutaneous coronary intervention primary pci
diagnostic and management of hand infection.

Conditions: Hand Infections; Including Whitlows; Tendinous Infections; Septic Arthritis

Summary: primary or secondary (post-traumatic infections, notably related to bites, wounds, etc.) infections of the hand are very common situations, even if the epidemiology is poorly understood. for example, hand bite injuries represent 1.2 million referrals to the healthcare system per year in the united states. their nosological framework extends from simple infections of the skin and soft tissues such as whitlows, to potentially severe deep damage such as arthritis and osteitis, or phlegmons of the tendon sheaths. the diagnostic approach is not consensual, and the contribution of additional biological parameters (inflammatory syndrome) and morphological investigations (x-rays, ultrasound, ct-scan or mri) is not codified. microbiology seems dominated by staphylococcus aureus, but few studies have precisely described the microbial etiology. consequently, probabilistic antibiotic therapy and the need to take bacteriological samples for secondary adaptation are not standardized. likewise, surgical strategies (abstention, systematic washing or depending on evolution) remain operator dependent. we consequently aim to described diagnostic, management and related outcomes or hand infections in a specialized tertiary care center.


Eligibility criteria:
inclusion criteria: * all patient ≥ 18 * yo followed-up for a hand infection in our tertiary care center * from 01/01/2014 to 31/12/2023, including * whitlows * tendinous infections * septic arthritis exclusion criteria: * osteomyelitis

Keywords: hand infection whitlows tendinous infections septic arthritis
facilitating functional independence in patients receiving prolonged mechanical ventilation

Conditions: Muscle Weakness

Summary: the primary aim of this proposal is to test the effectiveness of neuromuscular electrical stimulation (nmes) in improving functional status and muscle function in patients receiving prolonged mechanical ventilation.


Eligibility criteria:
inclusion criteria: * duration of mechanical ventilation \>14 days * sufficiently awake * able to speak and comprehend english * willingness to participate exclusion criteria: * cardiopulmonary instability * acute-onset neuromuscular disease * lower-extremity amputee or paresis * open wound at electrode application points * pitting edema grade ≥3 * presence of pacemaker, implanted defibrillator, or ventricular-assist device * inability to transfer from sitting to standing before critical illness

Keywords: muscle strength muscle function functional status
time-restricted eating acceptability, efficacy and safety in obesity

Conditions: Time Restricted Eating

Summary: a randomized controlled trial to determine adherence, acceptability and safety of time restricted eating (tre) in healthy, sedentary, free-living adults with obesity between the ages of 19-65 years when following 16:8 tre for 8 weeks. this 9-week study includes a baseline week and 8 weeks of the intervention period. participants are randomly assigned to the tre or the non-fasting control group. the tre group will consume calorie containing food and drink only over an 8 hour period and rest of the 16 hour would be fasting. adherence to tre and calorie intake are the primary outcomes. motivators, facilitators and barriers to tre, hunger and cravings levels, weight bias internalization, body composition (weight, body fat%, fat mass and muscle mass) , healthy eating index (hei) to assess diet quality, skin carotenoid levels, disordered eating risk, sleep quality, and perceptions of health and well-being are secondary outcomes.


Eligibility criteria:
inclusion criteria: * age 19 to 65 years * owns a smartphone * apparently healthy * bmi ( more than or equal to 25 kg/m2 ) and high body fat percent (bf%) (≥25% and ≥35% for males and females, respectively) * sedentary lifestyle (less than 150 minutes of self-reported moderate to vigorous activity per week) * self-reported eating interval of ≥12 h per day exclusion criteria: * diagnosed diabetes mellitus (type i or ii), coronary heart disease, heart failure, hypertension, hyperlipidemia, stroke, chronic lung diseases, liver or kidney disease, adrenal diseases, musculoskeletal disorders, uncontrolled thyroid disease (dose changes within the past 3 months), crohn's disease, ulcerative colitis, arthritis, undergoing active cancer treatment except for non-melanoma cancer, uncontrolled psychiatric disorder (a history of hospitalization for psychiatric illness). * currently taking any medication that is meant for, or has a known effect on, appetite * on anabolic steroid or hormone replacement therapy * participation in an exercise/nutrition/ weight-loss program within the last 6 months * any history of surgical intervention for weight management * having a ≥5% body weight change during the last 3 months * pregnant or less than 6 months post-partum, breastfeeding, polycystic ovarian syndrome or irregular menstruation * missing limbs, have a pacemaker or metal implants, * eating disorders or eat-26 score \>20 * alcohol or drug addiction * current smoker * works night shifts * unable to commit to a 9-week study * not willing to follow study protocol and any other contraindications. * currently following any of the following restrictive diets - keto/low carbohydrate/ vegan/ vegetarian/ intermittent fasting/ paleo/ calorie restriction/ any other restrictive diet * participating in another study

Keywords: time restricted eating obesity intervention 9 weeks randomization intermittent fasting
emerald: endocrine therapy omission with radiation in er+ breast cancer: assessing quality of life and disease control: a prospective phase ii trial

Conditions: Breast Cancer

Summary: this clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

primary objective: to determine the 3- year dmfs rate of radiotherapy as adjuvant monotherapy for early stage, low risk breast cancers in patients aged ≥ 60 years secondary objectives: 1. to determine the hrqol of patients ≥ 60 years with early stage, low risk breast cancer receiving adjuvant monotherapy with radiotherapy 2. to determine the 3-year and 5-year risk of ipsilateral breast tumor recurrence (ibtr) for early-stage breast cancers treated with lumpectomy and adjuvant radiotherapy without endocrine therapy 3. to quantify the 3-year and 5-year rates of local-regional recurrence, contralateral breast cancer, breast cancer-specific survival and overall survival and the 5 year rate of dmfs 4. to determine the 5-year utilization of salvage mastectomy and other salvage therapies 5. to determine late (up to 11 year) oncologic outcome data for patients accessible via chart review or phone call 6. to determine the toxicities experienced by patients ≥ 60 years with early stage, low risk breast cancer receiving adjuvant monotherapy with radiotherapy

Eligibility criteria:
inclusion criteria: 1. diagnosis of pathologically-confirmed invasive breast cancer 2. age ≥ 60 years 3. treatment with breast conserving surgery 4. pathologic t stage of t1 or t2 with total tumor size ≤ 3cm including any component of dcis that may exist in conjunction with invasive disease 5. ki-67 ≤ 20% 6. final surgical margins negative, defined as no tumor on ink. lobular carcinoma in situ involving the final surgical margin will be disregarded. 7. tumor must be estrogen receptor positive, progesterone receptor positive and her2neu non-amplified as per current college of american pathologists guidelines 8. clinical nodal stage cn0 9. if pathologic nodal staging is obtained, then pn0 or pn0(i+) 10. patients have had or have a scheduled discussion with a breast medical oncologist regarding adjuvant treatment options exclusion criteria: 1. node positive disease (n1-3) 2. metastatic disease (m1) 3. grade 3 disease and lymphovascular space invasion in the tumor 4. synchronous bilateral breast cancer 5. receipt of neoadjuvant therapy 6. diagnosis of a collagen vascular disease associated with an increased incidence of radiation toxicities such as scleroderma or systemic lupus erythematosis 7. diagnosis of other cancer within the prior 5 years, excluding basal or squamous cell carcinoma of the skin that has been treated 8. patient with psychiatric illness/social situations that would limit compliance with study requirements 9. prior radiotherapy to the index breast or recurrent cancer of the breast 10. known carrier of a mutation associated with predisposition to breast cancer development, including brca1 or brca2